Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

What Was Tested

The trial (phase 4) is built around Semaglutide.

GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.

It had 1 arm (groups): Semaglutide (experimental).

The registry classes the interventions as drug.

More on the Plan

Patients who meet eligibility criteria and who provide informed consent will be enrolled to receive semaglutide.

Following enrollment, all participants will undergo a baseline visit, a 1-month telephone follow-up visit, 3-month visit, 6-month and a 12-month (Close-out) visit.

Who Took Part

Enrollment: 20 planned participants were the target.

It was open to men only aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a physician diagnosis of PC. Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor). ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia.

The full record lists 5 inclusion and 6 exclusion criteria; among the exclusions: type 1 diabetes; taking a glp-1 ra; \<18 years of age.

How the Study Was Run

Design: single-group and open-label.

Being open-label, the Semaglutide study did not mask who received what.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2025-07-02 with completion listed for 2027-10-31.

It ran at 1 site in Canada.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Number of Serious Adverse Events (time frame: 12 months). Number of Adverse Events leading to Drug Discontinuation (time frame: 6 months). Measure of Weight (time frame: 12 months).

What This Means in Plain Language

Put simply, this is a phase 4 trial of Semaglutide in 20 people.

Its size is small, so on its own it can only give an early look.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.